UK Gynecologic Oncology Fellowship

Fellowship Director: Frederick R. Ueland, M.D.

The University of Kentucky Gynecologic Oncology Fellowship Program is fully accredited by the ACGME and approved for a complement of 5 fellows who are accepted in a 2-1-2 alternating schema. We offer the following fellowship tracks:

The University of Kentucky Gynecologic Oncology Fellowship Program is fully accredited by the ACGME and approved for a complement of 5 fellows who are accepted in a 2-1-2 alternating schema. We offer the following fellowship tracks:

  1. 1.       3-year
    • 12 consecutive months of research followed by 24 months of clinical training
    • Offered every year
  1. 2.       4-year (academic career)
    • 24 consecutive months of research followed by 24 months of clinical training
    • Offered every other year (interview odd years and enroll July 1 of even years) 
    • Candidate for NIH T-32 Surgical Scientists Training grant
    • Classwork toward a Masters or PhD degree to be completed prior to graduation

Upon completion of the fellowship, graduates will have the necessary skills to accept an academic position, evaluate and manage all patients with gynecologic malignancies, prescribe and manage chemotherapy, implement cancer education programs, perform meaningful translational research, participate in collaborative group trials, and assume a leadership role in cancer centers. A first-author published thesis of original research is a graduation requirement.

The Division has eight faculty and six full-time physicians who provide comprehensive cancer care for women from the Commonwealth of Kentucky and the surrounding region. Four faculty members are recognized as Best Doctors® and three are also Top Doctors® in America. Annual patient care volumes include: 5,000 outpatient visits, 1,300 chemotherapy cycles, 1,000 surgical operations including 250 robotic-assisted procedures. The robust clinical volumes give fellows exposure to the procedures necessary to demonstrate competency in all aspects of gynecological cancer care. Quality, safety, effectiveness and ethical conduct are emphasized. A weekly multi-disciplinary Tumor Conference integrates the principles of surgery, surgical pathology, radiation oncology, adjuvant therapy, and serves as dynamic education for trainees. The Division is a leader in enrollment for screening and therapeutic clinical trials, including investigator-initiated, collaborative group, and industry trials. Over the last few years, divisional publications have appeared in THE LANCET Oncology, Cancer, Obstetrics and Gynecology, Gynecologic Oncology, International Journal of Surgical Oncology, Neoplasia, Journal of Women’s Health, Journal of Pediatric Surgery, Pathology, Cancer Investigation, the American Journal of Obstetrics and Gynecology, Surgical Oncology, Annals of Surgical Oncology, and Clinical Obstetrics and Gynecology.

The Division of Gynecologic Oncology is an integral part of the NCI-designated Markey Cancer Center (MCC) at the University of Kentucky. Under the leadership of Dr. Mark Evers, the MCC now includes 28 departments from eight different colleges at the University. Since its establishment in 1983, the MCC has experienced a steady increase in the number of faculty, research programs, funding, space, and recognition. The MCC is organized into four thematic research programs: 1) Cancer Cell Biology and Signaling, 2) Cancer Prevention and Control, 3) Drug Discovery, Delivery and Translational Therapeutics, and 4) Genomic Instability, Epigenetics and Metabolism. There are also five established shared resource facilities: Biospecimen Procurement and Translational Pathology; Biostatistics and Bioinformatics; Cancer Research Informatics; Flow Cytometry and Cell Sorting; and Redox Metabolism. The MCC inpatient care facilities include the recently completed Pavilion A and the newly renovated Women’s Hospital in the MCC Roach Building.  Outpatient clinics, Outpatient Chemotherapy and Infusion, the Precision Medicine Clinic, the Combs Research Building, and the Whitney Hendrickson Women’s Cancer Facility are all in adjacent buildings. Recent construction includes 40,000 square feet of space in the new Bio-Pharmaceutical Building and 15,377 square feet of dedicated cancer research laboratories in the Biomedical/Biological Science Research Building.

UK HealthCare is the #1 hospital in Kentucky as ranked by the U.S. News & World Report. The hospital system has experienced extraordinary growth over the last 10 years, and is now among the largest 30 percent of academic medical centers in the nation. Since 2003, discharges and operating revenue have increased by 80 and 140 percent, respectively. Completed in 2011, the 512-bed $762M Pavilion A is the marquis addition to the hospital complex.